about
ABCA12 regulates ABCA1-dependent cholesterol efflux from macrophages and the development of atherosclerosisThe neuronal noradrenaline transporter, anxiety and cardiovascular diseaseAntiadrenergic effect of chronic amiodarone therapy in human heart failureProliferation of neointimal smooth muscle cells after arterial injury. Dependence on interactions between fibroblast growth factor receptor-2 and fibroblast growth factor-9Regional homovanillic acid production in humansMore rigorous protocol adherence to intensive structured management improves blood pressure control in primary care: results from the Valsartan Intensified Primary carE Reduction of Blood Pressure studyEffect of sunlight and season on serotonin turnover in the brain.A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.Assessing cardiovascular risk in regional areas: the Healthy Hearts Beyond City Limits program.Effect of propranolol on noradrenaline kinetics in patients with essential hypertension.Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial.Large artery stiffness: structural and genetic aspects.Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council oProtective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy.Cardiac sympathetic nerve biology and brain monoamine turnover in panic disorder.Outlook: finding improved medicines: the role of academic-industrial collaboration.Compound 21, a selective agonist of angiotensin AT2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo.Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.Promoting physiological hypertrophy in the failing heart.Chronic mental stress is a cause of essential hypertension: presence of biological markers of stress.Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillationPredictors of mean arterial pressure morning rate of rise and power function in subjects undergoing ambulatory blood pressure recording.Exercise and dietary influences on arterial stiffness in cardiometabolic disease.Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).Predictive Performance of Echocardiographic Parameters for Cardiovascular Events Among Elderly Treated Hypertensive Patients.Pet ownership and survival in the elderly hypertensive population.Plasma lipidomic analysis of stable and unstable coronary artery disease.Central nervous system noradrenergic control of sympathetic outflow in normotensive and hypertensive humans.Prediction of 10-year Risk of Incident Heart Failure in Elderly Hypertensive Population: The ANBP2 Study.Mechanical strain stimulates a mitogenic response in coronary vascular smooth muscle cells via release of basic fibroblast growth factor.Impact of nurse-mediated management on achieving blood pressure goal levels in primary care: Insights from the Valsartan Intensified Primary carE Reduction of Blood Pressure Study.Hypertensive Encephalopathy and Renal Failure in a Young Man.Regional 5-hydroxyindoleacetic acid production in humans.Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skeletal muscle in humans.Hydrocortisone-induced hypertension in men. The role of cardiac output.Optimising management of hypertension in primary care: the Valsartan Intensified Primary Care Reduction of Blood Pressure (Viper-Bp) study.Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGAltered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome.Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized AsseEffect of cardiac sympathetic nervous activity on mode of death in congestive heart failure.
P50
Q24316186-F56CC500-1533-43FF-AA71-05D3F7436A37Q28247061-263FB165-8D51-4273-B625-7D3B8B00F0F4Q28376427-4EB9AA77-8F47-44BF-9702-00A156219551Q28573776-5854632A-4D0F-4C5E-880F-BED742F657B4Q29393699-99DB2FE9-785E-4935-AE3F-AAB14E7F1B1FQ33572184-AC298E6C-5D97-44C4-A70B-D06204B15509Q34164438-C903E40E-33F8-4EBA-8B2C-7936ED8365EEQ34176994-86E538C5-5807-46DB-89D9-2158515ADD5AQ34401968-14223EC1-E9A7-4CBC-A1C1-79353C4A64F5Q34449080-8B638EF4-672F-4A1C-A246-CB25C7D5473DQ34483942-44C7F2DA-0FBB-48BA-98F9-06760534E120Q34570436-2258C4F1-1632-49AF-9A76-320A496456F6Q34742302-09D4BCE0-1F92-4FEB-9EFC-64D09EED4F4EQ35578778-41D0EF03-D2A2-42A7-A38A-CBC7DAB934C0Q35829348-4EC5FB2F-5F0F-4208-AFBA-EAE03DEF0133Q36296129-B49B2C3B-F181-402A-821B-A23C656AE14DQ36546985-71FFC653-32B8-46CE-AE6D-3C1C229E99C9Q36745702-D67CD21E-7D38-408A-9D24-F1E96CA57BFAQ37097122-6C91BC05-7884-426C-B212-E623C299476EQ37097151-E3D35ABF-F566-42DD-8BFD-B71BA755DFDFQ37316471-57BBBD85-5E24-470B-AFDE-190D6FC5644CQ37662587-2A8B7026-445C-4913-87BB-21CE7A031F7FQ38187101-F91C247D-E076-4E01-ADDF-5DA3BDCE8DE8Q38483915-D579ED82-559C-45C7-B1B1-F8D50A2F7AF1Q38875978-87F15A36-B40A-4F10-BEB2-F4365B79FD90Q39068721-BE941F3F-3678-494C-970C-BBE4754920ABQ39709364-D846AFF7-3ECB-49E6-ADF3-DA106D04430AQ40516349-BEDBB3C2-5CA3-43E9-AD3A-9FE7E76F849DQ40577451-7D501207-910D-4092-B981-27F04C64EE77Q40766448-FA0E4CB2-5F1E-4F52-B112-9EEB635114B5Q40822265-A7A9F6FB-E932-4504-8AA2-25FE4A59FFB9Q41103715-9C5232C0-6EB4-462F-9C17-D882A1AB3202Q41666184-EB1C798D-E026-40FD-9782-BEEB4208F1D5Q41937364-4F4741EF-A735-497C-874C-D5B3EB3B7426Q42558194-7CB7EF46-AE5A-4FC5-9327-9C17F018028AQ42685610-4AF6B4A8-15B1-48A9-9C16-55AA190E0067Q43236941-2B55A0D3-E09E-4910-99FD-1B7F42AD5A0BQ43266246-E87ACD42-7D2C-4B0B-BA4E-CF3CAE984329Q43273403-8BED2839-FA66-419D-AD0D-90FD949A3886Q43655249-EAE2C326-C4F6-4B37-B534-4C8F4C97574E
P50
description
Wissenschaftler
@de
scientist
@en
wetenschapper
@nl
name
Garry L Jennings
@af
Garry L Jennings
@an
Garry L Jennings
@ang
Garry L Jennings
@ast
Garry L Jennings
@bar
Garry L Jennings
@bs
Garry L Jennings
@ca
Garry L Jennings
@co
Garry L Jennings
@cs
Garry L Jennings
@cy
type
label
Garry L Jennings
@af
Garry L Jennings
@an
Garry L Jennings
@ang
Garry L Jennings
@ast
Garry L Jennings
@bar
Garry L Jennings
@bs
Garry L Jennings
@ca
Garry L Jennings
@co
Garry L Jennings
@cs
Garry L Jennings
@cy
prefLabel
Garry L Jennings
@af
Garry L Jennings
@an
Garry L Jennings
@ang
Garry L Jennings
@ast
Garry L Jennings
@bar
Garry L Jennings
@bs
Garry L Jennings
@ca
Garry L Jennings
@co
Garry L Jennings
@cs
Garry L Jennings
@cy
P106
P1153
7202261143
P21
P31
P496
0000-0002-7865-5483